/

Empresas

Ad

No verificado

Adcendo

Sobre qué escribimos

BiologíaEconomíaFarmacéuticaFinanzasSanidad

8 Comunicados de prensa

Ver todos los comunicados de prensa

Press Release cover image

20/04/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Fuente

Editor

1.00

0

Press Release cover image

14/04/2026

Salud

Fitness

Economía

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

Fuente

Editor

1.00

0

23/04/2025

Farmacéutica

Sanidad

Finanzas

Biología

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Fuente

Editor

1.00

0

01/04/2025

Farmacéutica

Sanidad

Economía

Gestión empresarial

Administración de Empresas

Biología

Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

Fuente

Editor

1.00

0

26/02/2025

Farmacéutica

Sanidad

Biología

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

Fuente

Editor

1.00

0

Press Release cover image

25/11/2024

Farmacéutica

Sanidad

Finanzas

Banca

Préstamos

Ahorro/Finanzas personales

Leasing

Gestión de bonos y obligaciones

Fondos de inversión

Eurobonos

Biología

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

Fuente

Editor

1.00

0

08/10/2024

Farmacéutica

Sanidad

Biología

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

Fuente

Editor

1.00

0

20/08/2024

Farmacéutica

Sanidad

Economía

Patentes, marcas y derechos de autor

Biología

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0